Comparative Evaluation of B-Type Natriuretic Peptide, Mid-Regional Pro-A-type Natriuretic Peptide, Mid-Regional Pro-Adrenomedullin, and Copeptin to Predict 1-Year Mortality in Patients With Acute Destabilized Heart Failure

Journal of Cardiac Failure

Volumn 13, Issue 1, 2007, Pages 42-49

  Gegenhuber, Alfons ^a   Struck, Joachim ^c   Dieplinger, Benjamin ^b   Poelz, Werner ^d   Pacher, Richard ^e   Morgenthaler, Nils G ^c   Bergmann, Andreas ^c   Haltmayer, Meinhard ^b,f   Mueller, Thomas ^b  

^a Departments of Internal Medicine   (Austria)

^b Laboratory Medicine   (Austria)

^c BRAHMS AG   (Germany)

^d JOHANNES KEPLER UNIVERSITY LINZ   (Austria)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Adrenomedullin; Natriuretic peptides; Prognosis; Vasopressin

Indexed keywords

ADRENOMEDULLIN; ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

ACUTE HEART FAILURE; AGED; AREA UNDER THE CURVE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HOSPITAL CARE; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; ROC CURVE; STATISTICAL ANALYSIS; SURVIVAL; TERTIARY HEALTH CARE;

AGED; AGED, 80 AND OVER; ATRIAL NATRIURETIC FACTOR; FEMALE; GLYCOPEPTIDES; HEART FAILURE, CONGESTIVE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROTEIN PRECURSORS; PROTEINS; ROC CURVE;

EID: 33847402992     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2006.09.004     Document Type: Article

References (26)

1. Cowie M.R., Jourdain P., Maisel A., Dahlstrom U., Follath F., Isnard R., et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 24 (2003) 1710-1718
2. Pfister R., and Schneider C.A. Natriuretic peptides BNP and NT-pro-BNP: established laboratory markers in clinical practice or just perspectives?. Clin Chim Acta 349 (2004) 25-38
3. Lee D.S., Austin P.C., Rouleau J.L., Liu P.P., Naimark D., and Tu J.V. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 290 (2003) 2581-2587
4. Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr Rev 24 (2003) 341-356
5. Doust J.A., Pietrzak E., Dobson A., and Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330 (2005) 625
6. Schrier R.W., and Abraham W.T. Hormones and hemodynamics in heart failure. N Engl J Med 341 (1999) 577-585
7. Morgenthaler N.G., Struck J., Thomas B., and Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 50 (2004) 234-236
8. Nicholls M.G., Charles C.J., Lainchbury J.G., Lewis L.K., Rademaker M.T., Richards A.M., et al. Adrenomedullin in heart failure. Hypertens Res 26 (2003) S135-S140
9. Morgenthaler N.G., Struck J., Alonso C., and Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 51 (2005) 1823-1829
10. Sanghi P., Uretsky B.F., and Schwarz E.R. Vasopressin antagonism: a future option in heart failure. Eur Heart J 26 (2005) 538-543
11. Morgenthaler N.G., Struck J., Alonso C., and Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52 (2006) 112-119
12. Mueller T., Gegenhuber A., Poelz W., and Haltmayer M. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 91 (2005) 606-612
13. Gegenhuber A., Mueller T., Dieplinger B., Poelz W., Pacher R., and Haltmayer M. B-type natriuretic peptide and amino terminal proBNP predict one-year mortality in short of breath patients independently of the baseline diagnosis of acute destabilized heart failure. Clin Chim Acta 370 (2006) 174-179
14. Hanley J.A., and McNeil B.J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148 (1983) 839-843
15. Eichhorn E.J. Prognosis determination in heart failure. Am J Med 110 (2001) 14S-36S
16. Clerico A., and Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 50 (2004) 33-50
17. Nishikimi T., Yoshihara F., Mori Y., Kangawa K., and Matsuoka H. Cardioprotective effect of adrenomedullin in heart failure. Hypertens Res 26 (2003) S121-S127
18. Pousset F., Masson F., Chavirovskaia O., Isnard R., Carayon A., Golmard J.L., et al. Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure. Eur Heart J 21 (2000) 1009-1014
19. Richards A.M., Doughty R., Nicholls M.G., MacMahon S., Sharpe N., Murphy J., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 37 (2001) 1781-1787
20. Gottlieb S.S., Kukin M.L., Ahern D., and Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 13 (1989) 1534-1539
21. Valdemarsson S., Bergdahl A., and Edvinsson L. Relationships between plasma levels of catecholamines and neuropeptides and the survival time in patients with congestive heart failure. J Intern Med 235 (1994) 595-601
22. Richards A.M., Doughty R., Nicholls M.G., Macmahon S., Ikram H., Sharpe N., et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation 99 (1999) 786-792
23. Rouleau J.L., Packer M., Moye L., de Champlain J., Bichet D., Klein M., et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 24 (1994) 583-591
24. Robertson G.L. The use of vasopressin assays in physiology and pathophysiology. Semin Nephrol 14 (1994) 368-383
25. Bettencourt P., Azevedo A., Pimenta J., Frioes F., Ferreira S., and Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 110 (2004) 2168-2174
26. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., and Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130